Corporate Highlights from 1Q 2026 to date
Advanced initial commercial adoption of FemaSeed Complete, positioning Femasys to expand access to first-line fertility treatment through integrated, in-office care by OB/GYNs, supporting earlier intervention prior to referral to higher-cost specialty care.
Launched FemaSeed Complete at ACOG 2026, advancing commercialization and expanding provider awareness to support adoption of first-line fertility treatment in the OB/GYN office.
Established strategic partnership with AMI Technologies to introduce and commercialize its fertility portfolio in Israel, expanding international market opportunities.
Appointed John Canning as Chief Operating Officer, enhancing leadership to drive operational execution and support commercial growth.
Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, enhancing leadership and strategic oversight.
Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc®, advancing toward U.S. approval of a first-of-its kind, non-surgical permanent birth control.
FemBloc permanent birth control system achieved Medical Device Single Audit Program (MDSAP) certification, supporting global regulatory readiness and future market access.
Received AMA CPT Editorial Panel approval of a new Category III CPT code for FemaSeed intratubal insemination (ITI), supporting future reimbursement and broader adoption in the U.S.
Entered a strategic distribution partnership with OR Consulting to support commercial launch of FemBloc, FemaSeed, and other portfolio products in Switzerland, expanding European market access.
Established partnership with Refuah Health Center, advancing adoption of FemaSeed as a first-line infertility treatment and expanding access through community-based care.
"During the first quarter of 2026 and into the second quarter of 2026, we delivered meaningful clinical, regulatory and commercial progress across our FemBloc and FemaSeed platforms," said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. "We are accelerating commercialization of FemaSeed with the introduction of the FemSperm® product family, enabling OB/GYNs to deliver integrated, in-office fertility care. Concurrently, we advanced FemBloc with initiation of patient enrollment in the FINALE pivotal clinical trial, a key step toward U.S. FDA approval. We believe our current cash resources are sufficient to fund operations into the third quarter of 2026. We remain focused on scaling a broad portfolio of innovative women's health solutions globally, addressing critical unmet needs with safe, technologically advanced products."
Financial Results for Quarter Ended March 31, 2026
Sales increased by $83,625, or 24.5%, to $424,889 in 2026 from $341,264 in 2025, primarily due to sales of FemBloc.
Research and development expenses decreased by $1,659,071, or 55.9%, to $1,309,401 in 2026 compared to $2,968,472 in 2025, primarily reflecting the transition of development products into inventory to support commercialization, along with lower development, clinical, compensation, and professional service costs.
Net income, including gains from changes in fair value of financial instruments, was $846,100, or $0.00 per basic and diluted share attributable to common stockholders for the quarter ended March 31, 2026, compared to a net loss of $5,896,839, or ($0.23) per basic and diluted share attributable to common stockholders, for the quarter ended March 31, 2025.
Cash and cash equivalents as of March 31, 2026, was approximately $5.4 million and the Company had an accumulated deficit of approximately $145.0 million. The Company expects, based on its current operating plan, its current cash and cash equivalents will be sufficient to fund its ongoing operations into the third quarter of 2026.
For more information, please refer to the Company's Form 10-Q filed May 8, 2026, which can be accessed on the SEC website.
FEMASYS INC.
Condensed Balance Sheets
(unaudited)
Assets
March 31,2026
December 31,2025
Current assets:
Cash and cash equivalents
$
5,386,041
9,266,353
Accounts receivable, net
172,264
616,600
Inventory
6,105,267
5,740,249
Prepaid and other current assets
679,917
833,133
Total current assets
12,343,489
16,456,335
Property and equipment, at cost:
Leasehold improvements
1,238,886
1,238,886
Office equipment
80,941
78,155
Furniture and fixtures
421,798
417,876
Machinery and equipment
3,095,633
3,065,713
Construction in progress
955,271
897,885
5,792,529
5,698,515
Less accumulated depreciation
(3,868,518
)
(3,802,940
)
Net property and equipment
1,924,011
1,895,575
Long-term assets:
Lease right-of-use assets, net
1,178,941
1,297,121
Intangible assets, net of accumulated amortization
124,252
134,914
Other long-term assets
924,552
940,232
Total long-term assets
2,227,745
2,372,267
Total assets
$
